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Abstract
Pheochromocytomas are rare catecholamine-secreting neuroendocrine tumors derived 
from chromaffin tissue of the adrenal medulla. Such tumors arising from the  sympathetic 
ganglia of the thorax, abdomen, or pelvis are termed “paragangliomas” or “ extra-adrenal 
pheochromocytomas.” The classic symptoms of these tumors are due to excess  circulating 
levels of norepinephrine, epinephrine, or dopamine. Although 21% may be  asymptomatic, 
the most common symptoms associated with pheochromocytomas include  sweating, pal-
pitations, and headaches in association with intermittent  hypertension. If left untreated, 
excess catecholamines may result in hypertensive crisis leading to cardiac complica-
tions, cerebrovascular stroke, or ultimately sudden death. These catecholamine-secret-
ing tumors are most commonly sporadic, but about 30% of patients have this disease 
as part of a familial disorder such as multiple endocrine neoplasia type 2 (MEN2) or 
von  Hippel-Lindau (VHL) syndrome. Although most are benign, accurate recognition of 
pheochromocytomas with malignant potential and distant metastases remains a major 
diagnostic challenge. Advances in the field of molecular genetics have led to novel diag-
nostic and therapeutic strategies in an attempt to address this dilemma. Surgical excision 
of pheochromocytomas and paragangliomas is the mainstay of treatment and offers the 
only potential for cure. This chapter focuses on recent developments in the diagnosis of 
pheochromocytomas, encompassing biochemical, radiologic, histologic, and molecular 
analyzes. In addition, novel therapeutic strategies and advances in individualized tar-
geted therapies for malignant pheochromocytomas will be discussed.
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1. Introduction
Pheochromocytomas are catecholamine-secreting tumors that arise from chromaffin cells 
of the adrenal medulla. Extra-adrenal pheochromocytomas or “paragangliomas” are those 
 catecholamine-secreting tumors, which arise from the sympathetic ganglia. Whereas  adrenal 
and extra-adrenal pheochromocytomas present and are treated similarly, the distinction 
between them is important for risk for malignancy, implications for associated neoplasms, and 
genetic testing. These rare neoplasms have an estimated annual incidence of  approximately 
0.8 per 100,000 person-years, and among people with hypertension in an outpatient setting, 
the prevalence varies between 0.2 and 0.6% [1–3]. Additionally, other tumors are discov-
ered on autopsy such that the prevalence is likely to be underestimated [4]. The incidence of 
hereditary pheochromocytomas is estimated to be >30% in affected lineages [5]. Hereditary 
 pheochromocytomas have been associated with >10 different germline mutations and are 
frequently a feature of a familial disorder or tumor syndrome, all of which have autosomal 
dominant inheritance (Table 1). They are also more likely to be malignant and bilateral than 
sporadic pheochromocytomas and present at younger ages.
Although pheochromocytomas may occur at any age, sporadic tumors are most com-
mon in the fourth to fifth decade, and there is no sex predilection [6]. The majority of 
 pheochromocytomas and paragangliomas are benign and are associated with a normal life 
expectancy following treatment [7]. The incidence of malignancy is difficult to determine 
but ranges from 2.4 to 50% and higher among abdominal paragangliomas and those tumors 
harboring SDHB gene mutations [8–10]. Malignant pheochromocytomas often demonstrate 
local invasion, metastases, or recurrence and carry a worse prognosis with five-year survival 
rates of 20–70% [10–14].
Gene Syndrome Penetrance Frequency of 
malignancy
PCC/PGL 
characteristics
Associated tumors
VHL Von 
Hippel-Lindau
Autosomal dominant
Variable expression
<10% Young age (mean 28)
Bilateral/multifocal
Retinal angiomas
Hemangioblastoma
Clear cell RCC
NF1 Neurofibromatosis Autosomal dominant <10% Mean age 41
Bilateral disease 
common
Extra adrenal PGL 
rare
Neurofibroma
Neurofibrosarcoma
Glioma
Astrocytoma
Carcinoid
Leukemia
RET MEN II Autosomal dominant <5%
Extra-adrenal 
PGL rare
Mean age 40
Hyperparathyroidism
No increased 
malignancy risk
Medullary thyroid 
cancer
Mucosal neuromas
SDHC PGL 3 Autosomal dominant <5% Mean age 46
Extra adrenal head & 
neck PGLs
Bilateral/multifocal
Amyloidosis
Cutaneous lichen
GISTs
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2. Clinical presentation
Since >50% of patients with pheochromocytomas are asymptomatic, these adrenal tumors are 
often identified as an “incidentaloma” on imaging studies obtained for other medical  reasons 
or in patients with one of the hereditary syndromes of which pheochromocytomas are a 
 feature. Symptoms reflect excessive secretion of norepinephrine, epinephrine, or  dopamine 
into the circulation, and they are typically paroxysmal. The known triad of episodic head-
aches, sweating, and tachycardia occurs in about 40% of patients, although the majority will 
have two of these three classic symptoms [15]. Generalized sweating occurs in up to 70% 
of symptomatic patients. Other symptoms include palpitations, tremor, pallor, dyspnea, 
generalized weakness, and panic attack-type symptoms. Rarely, pheochromocytomas may 
present with a new diagnosis of diabetes, more commonly seen in younger patients who 
have no known risk factors. Approximately 50% of patients have paroxysmal hypertension, 
about 35–40% primary hypertension, and 10–15% are normotensive. A rare presentation due 
to an excess of circulating catecholamines, hypertensive crisis can precipitate life-threatening 
cardiovascular emergencies such as a myocardial infarction, cardiomyopathy, or a cerebro-
vascular accident in patients with pheochromoctyomas. Most common stimuli for eliciting 
hypertensive crises are exercise, tumor manipulation, and/or anesthesia, and for this reason, 
optimal preoperative and intraoperative management are essential [16].
Historically, pheochromocytomas and paragangliomas were thought to obey the “Rule of 10s”: 10% 
malignant, 10% bilateral, 10% hereditary, 10% extra-adrenal, 10% children, 10%  nonhypertensive, 
Gene Syndrome Penetrance Frequency of 
malignancy
PCC/PGL 
characteristics
Associated tumors
SDHD PGL 4 Autosomal dominant 
with parent of origin 
effect
<5% Mean age 35
Extra adrenal head & 
neck PGLs
Bilateral/multifocal
Papillary thyroid 
cancer
GISTs
SDHB PGL 1 Autosomal dominant 34–70% Extra adrenal
Increased malignancy 
risk
Bilateral if adrenal
RCCs
GISTs
SDHAF2 PGL 2 Autosomal dominant 
with parent of origin 
effect
Uncertain
Head and 
neck PGLs
Extra adrenal GISTs
TMEM 127 Autosomal dominant 5% Adrenal
Bilateral
MAX Autosomal dominant 10% Adrenal
Bilateral
MEN, multiple endocrine neoplasia; PCC, pheochromocytoma; PGL, paraganglioma; RCC, renal cell carcinoma; GIST, 
gastrointestinal stromal tumor.
Table 1. Genetic mutations associated with pheochromocytomas and paragangliomas.
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and 10% calcified. However, this rule does not appear to hold true anymore, with recent advances 
in molecular biology demonstrating that >50% of tumors have a genetic link, 50% of tumors have 
malignant potential, and 25% of tumors arise in an  extra-adrenal location [17].
3. Hereditary pheochromocytomas: genetics
Pheochromocytomas have the strongest genetic component of endocrine tumors with up to 
50% being linked to germline and somatic mutations in 17 different genes [18]. The rate of 
genetic association is higher in children who develop pheochromocytomas with rates of up 
to 69% (Table 1) [19]. Other genetic conditions such as the Carney triad and  Carney-Stratakis 
 syndrome are known to be associated with development of paragangliomas, but the  underlying 
gene has not yet been identified. Multiple endocrine neoplasia type 2 (MEN 2) syndrome, 
subclassified into MEN 2A and MEN 2B, is associated with mutations in the  tyrosine kinase 
receptor proto-oncogene RET. Patients affected with MEN 2 typically present with medul-
lary thyroid cancer (MTC), and 50% will also have or develop pheochromocytomas. While 
half of these patients will have bilateral tumors, malignant transformation is rare [13, 20]. 
Patients with known MEN 2 now commonly undergo prophylactic total  thyroidectomy and 
have ongoing imaging surveillance for development of a pheochromocytoma. As with MEN 
2, von Hippel Lindau (VHL) and neurofibromatosis type 1 (NF1) are characterized by a pre-
disposition to multiple tumor types. The rate of pheochromocytoma development in NF1 is 
significantly lower than in VHL or MEN 2 syndromes; however, the metastatic rate for NF1-
associated pheochromocytomas of approximately 12% is higher than with MEN 2 or VHL 
[21]. The Carney Syndrome (or Carney Complex) is a triad of tumors, which includes the 
development of paragangliomas. First described in 1977, this complex includes the occurrence 
of pulmonary chondroma, gastrointestinal stromal tumors, and functioning paragangliomas 
in affected young women [22]. Carney-Stratakis syndrome is the association of familial para-
ganglioma with gastric stromal sarcomas. It is considered to be a distinct condition from the 
Carney Complex as it is not associated with pulmonary chondroma, and it exhibits an autoso-
mal dominant pattern of inheritance [23].
Up to 25% of apparent sporadic cases result from germline loss-of-function mutations in the 
genes encoding the subunits A[F2], B, C, and D of succinate dehydrogenase (SDH) [24–27]. 
The SDH enzyme is involved in the Krebs cycle, where it catalyzes the oxidation of succinate 
to fumarate and also in the respiratory electron transfer chain, where it transfers electrons 
to coenzyme-Q. Germline mutations in the SDH gene complex give rise to the hereditary 
paraganglioma (PGL) and pheochromocytoma syndromes of which there are four. These 
syndromes are termed PGL1, PGL2, PGL3, and PGL4 and are attributable to mutations in 
SDHD, SDHAF2, SDHC, and SDHB, respectively [28]. In addition, germline mutations in 
the SDH gene have been identified in other hereditary paraganglioma syndromes such as 
 Carney-Stratakis syndrome [29], whereas SDHB mutations are found in approximately 
1.7–6.7% of sporadic pheochromocytomas and linked to more aggressive thoracic or intra-
abdominal paragangliomas with younger age of presentation, multiple tumors, and higher 
metastatic rates [30]. SDH-related tumors are typically extra-adrenal, although some cases of 
adrenal pheochromocytomas have been reported. These patients also have an increased risk 
of renal cell carcinoma, which can have a more aggressive phenotype earlier in life [31].
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Due to rapid developments in molecular research over the past decade, several additional 
genes have been identified that contribute to hereditary pheochromocytomas. These include 
myc-associated factor X (MAX) mutations that have been identified in this gene in 1.12% of 
patients with no other known mutations [32], transmembrane protein 127 (TMEM127) [33], 
and most recently, hypoxia-inducible factor 2-alpha (HIF2A) [34]. Genetic testing in patients 
with pheochromocytomas is an important component of management, although not rou-
tinely performed in most sporadic cases, as it is both expensive and time-consuming. A 
study using next-generation sequencing of pheochromocytomas that analyzes multiple genes 
 simultaneously has proven highly sensitive in detecting mutations and may provide clinically 
relevant data in the future [35]. More patients with pheochromocytomas are being referred for 
 next-generation sequencing with the goal of optimizing surveillance protocols and  identifying 
family members at risk of developing pheochromocytoma for screening.
4. Diagnosis
4.1. Biochemical investigation
The diagnosis of pheochromocytoma is primarily made through biochemical investigations 
with subsequent anatomic and functional imaging delineating extent of disease. Guidelines 
from the Endocrine Society, European Society of Endocrinology, and American Association 
of Clinical Endocrinologists recommend the measurement of plasma or urinary  fractionated 
metanephrines (specifically, the O-methylated metabolites of catecholamines), as they are 
most accurate for diagnosis of pheochromocytoma, demonstrating excellent sensitivity 
(97%) and specificity (91%) [2]. Metanephrines are consistently elevated in patients with 
 biochemically active or functional pheochromocytomas despite fluctuating catecholamine 
release. When measuring 24-hour urinary metanephrines, urinary creatinine should also be 
measured to verify completeness of urine collection. For plasma metanephrine measurement, 
it is recommended that patients be in the supine position at least 30 min before blood is drawn 
[2]. It is also important prior to testing that any substances that may cause false-positive eleva-
tions in urinary or plasma metanephrine levels are discontinued, which includes certain anti-
hypertensives, antidepressants (particularly levodopa, tricyclic antidepressants, and selective 
serotonin reuptake inhibitors (SSRI)), and caffeine. If these ideal testing conditions are not 
met, false-positive rates can be as high as 41% [36]. Diagnostic levels of metanephrines for 
pheochromocytoma are defined as levels greater than three times the upper reference limit. 
In patients with elevated metanephrines, but to a level less than the diagnostic threshold, uri-
nary collection for metanephrines should be repeated to ensure correct conditions as stated 
above. If equivocal levels are confirmed,  further biochemical tests are required that include a 
clonidine suppression test, in which plasma normetanephrine levels will remain elevated in 
the presence of a functioning pheochromocytoma or paraganglioma [37]. In patients consid-
ered to be low risk for pheochromoctyomas, measuring plasma fractionated metanephrines 
is the first-line investigation as the predictive value of a negative test is extremely high and 
excludes such tumors, except in patients with early preclinical disease. If metanephrine levels 
are normal in asymptomatic patients, then no further evaluation is necessary unless patients 
have typical paroxysmal symptoms in which biochemical testing should be repeated during 
a spell. In this scenario, patients are instructed to start a 24-hour urine collection when they 
Pheochromocytomas
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have a typical spell. If results are still normal on repeat testing, other causes of spells should 
be investigated.
More recent studies have demonstrated the utility of plasma methoxytyramine in the  diagnosis 
of pheochromocytoma, particularly for detecting exclusively dopamine-secreting tumors, 
which are rare and therefore can sometimes be overlooked by measuring only metanephrines 
[38, 39]. Chromogranin A, a polypeptide secreted by chromaffin cells, is the most accurate 
general biomarker for neuroendocrine tumors. Although not used in routine  clinical practice, 
largely due to cost, chromogranin A is elevated in 91% of pheochromocytoma patients. While 
less specific, chromogranin A may be a valuable tool in monitoring response to treatment [40]. 
When chromogranin A is combined with catecholamine measurements, the sensitivity for 
diagnosis of pheochromocytoma approaches 100% and, in the majority of cases, normalizes 
after surgical resection of such tumors.
4.2. Radiologic studies
Once biochemical diagnosis of pheochromocytoma has been made, further evaluation with 
imaging is indicated to localize the primary tumor and assess for distant disease and allow 
for treatment planning including surgical resection. CT or MRI of the abdomen is initially 
performed to assess the adrenal gland. If these studies do not show an adrenal lesion in the 
presence of abnormal biochemical tests, then further imaging of the body is warranted [41]. 
CT and MRI are equally sensitive (98–100%) and specific (approximately 70%), and imaging 
choice depends upon cost, availability, and other issues such as radiation dose and use of 
contrast material. Historic concerns about contrast material provoking catecholamine release, 
and hypertensive crises have not been borne out in the literature; nonionic or low-osmolar 
contrast-enhanced CT is considered safe and does not require pretreatment with alpha- and 
beta-blockade [42]. The Endocrine Society recommends CT as the first-choice imaging modal-
ity because of its excellent spatial resolution for thorax, abdomen, and pelvis (Figure 1). 
MRI is the imaging modality of choice in patients with metastatic disease, head, and neck 
 paragangliomas, CT-contrast allergies, pregnant women, children, and patients in whom 
radiation exposure should be limited (Figure 2) [2].
Functional imaging including metaiodobenzylguanidine scintigraphy (MIBG), positron emis-
sion tomography (PET), or somatostatin receptor imaging may also be required to evaluate 
the extent of disease, looking predominantly for extra-adrenal glands, and to accurately stage 
patients. Functional imaging is also indicated when abdominal CT or MRI is negative in the 
presence of clinical and biochemical evidence of pheochromocytoma. MIBG scintigraphy, using 
the catecholamine precursor 123I- or 131I-metaiodobenzylguanidine that is taken up by adren-
ergic tissue, is the first-line functional imaging modality. MIBG is a compound resembling nor-
epinephrine that is taken up by adrenergic tissue. MIBG can identify tumors not detected by CT 
or MRI, in addition to localizing multiple or extra-adrenal tumors when CT or MRI abdomen 
is positive (Figure 3). Overall reported sensitivity and specificity of MIBG scanning is 94 and 
92%, respectively [20]. Patients taking certain medications  including tricyclic antidepressants, 
labetalol, and specific calcium antagonists should temporarily discontinue these drugs prior to 
scanning as they may interfere with 123I-MIBG uptake and image interpretation. 123I-MIBG 
has superior imaging quality than 131I-MIBG, and it is the radiotracer of choice when available 
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Figure 1. Axial CT imaging of a right adrenal heterogeneous mass measuring 34 hounsfield units on noncontrast phase. 
On enhanced and delayed series, the mass demonstrated relatively little washout and CT features are consistent for a 
pheochromocytoma.
Figure 2. Axial MRI showing a mass (white arrow) in the medial limb of the right adrenal gland with a heterogeneously 
high signal on T2-weighted imaging consistent for a pheochromocytoma.
Pheochromocytomas
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[43, 44]. A note of caution with regard to MIBG imaging is that its sensitivity is decreased in 
malignant pheochromocytomas [45]. This may be due to reduced expression of norepinephrine 
transporters in malignant adrenal tumors or dedifferentiation. It has been shown that tumors 
associated with VHL and SDHB genetic mutations may express a reduced number of noradren-
aline transporters and, therefore, are more likely to be negative on MIBG imaging [46, 47].
Single-photon emission computed tomography (SPECT) imaging has been used in combina-
tion with both CT and MRI to increase accuracy in tumor localization as it involves simul-
taneous acquisition of both morphologic and functional data (Figure 4). However, SPECT 
imaging can miss smaller lesions due to relatively low resolution. Positron emission tomogra-
phy (PET), using biologically active tracer-labeled molecules (18F-flurodeoxyglucose (FDG) 
most commonly), is increasingly employed in the diagnostic workup of pheochromocyto-
mas and paragangliomas, particularly in patients where MIBG is negative. Although the 
18F-FDG tracer is not specific for pheochromocytomas, it is useful in detecting pheochro-
mocytomas and paragangliomas that do not accumulate MIBG, and it is superior to other 
functional imaging techniques in patients with disease associated with SDHB mutations [46]. 
The Endocrine Society guidelines favor [18F-FDG] PET-CT as the preferred imaging modal-
ity over 123I-MIBG scintigraphy in patients with known metastatic disease [2]. Recently, 
more specific tracers including 18F-DOPA, 18F-FDA (fluorodopamine), and 11C-HED (meta-
hydroxephedrine) have been developed for pheochromocytoma and paraganglioma func-
tional imaging but are not yet widely available.
Figure 3. 123I-MIBG scan showing focal uptake in the right adrenal gland consistent for a pheochromocytoma.
Figure 4. SPECT/CT imaging demonstrates focal tracer uptake in the right suprarenal region (arrow) suspicious for a 
right adrenal pheochromocytoma.
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Image-guided needle biopsy of suspected pheochromocytomas should be avoided due to a 
high rate of biopsy-related complications such as triggering hypertensive crises, hematoma, 
severe pain, incorrect or inadequate biopsy, increased difficulty of surgical resection, and 
delay to definitive surgical treatment [48].
4.3. Histopathologic diagnosis of pheochromocytoma
The histologic diagnosis of pheochromocytomas is rather uncomplicated but difficulty arises 
when differentiating benign from malignant tumors. Tumor cells in pheochromocytomas and 
paragangliomas demonstrate a typical nested Zellballen pattern surrounded by sustentacu-
lar cells, which stain positive for S100 protein on immunohistochemistry. Characteristically, 
they exhibit immunopositivity for synaptophysin and chromogranin A and may express 
 neurofilament [49]. There are no absolute histologic criteria for the diagnosis of malignancy 
and no reliable means to identify patients with pheochromocytomas who are at the risk of 
recurrence or metastatic spread using standard histopathologic techniques. Several histologic 
scoring systems have been devised to guide pathologists in the diagnosis of malignancy. The 
pheochromocytoma of the adrenal gland scoring system (PASS), devised by Thompson in 
2002, is the most commonly used system (Table 2) [50]. In PASS, the histologic features of 
each pheochromocytoma are given a score, and the sum score is used to stratify the tumors 
into groups with potential for aggressive behavior (PASS > 4) and those likely to behave in a 
benign manner (PASS < 4). It is recommended that any patient with a PASS score of >4 should 
be closely followed [51]. However, this scoring system has limitations. It has been shown to 
have significant interobserver and intraobserver variation leading to recommendations that 
it be used with caution.
Features Score
Large nest of cells or diffuse growth >10% of tumor volume 2
Necrosis (confluent or central in large nests) 2
High cellularity 2
Cellular monotony 2
Presence of spindle shaped tumor cells 2
Atypical mitotic figures (>3 per 10 high power fields) 2
Extension of tumor into adjacent fat 2
Vascular invasion 1
Capsular invasion 1
Profound nuclear pleomorphism 1
Nuclear hyperchromasia 1
A PASS score of <4 suggest a pheochromocytoma likely to behave in a benign manner [50].
A PASS score of ≥4 indicates a tumor with potentially aggressive behavior (PASS ≥ 4).
Table 2. Pheochromocytoma of the adrenal gland scoring scale (PASS).
Pheochromocytomas
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Although several immunohistochemical markers of malignancy for  pheochromocytomas 
have been proposed, none have emerged as reliable candidates for routine use in  clinical 
practice. Markers that have been investigated to date include neuroendocrine-related and 
 catecholamine-related markers (neuropeptide Y, 3,4-dihydroxyphenylalanine),  granin-derived 
peptides (EM66, secretogranin II), CD-44s, angiogenic markers, and  regulators  (vascular 
endothelial growth factor (VEGF) and VEGFR), heat shock protein 90, and telomerase com-
plex proteins.
5. Treatment
The curative treatment of choice for pheochromocytomas is surgical resection. However, 
management of some pheochromocytomas (particularly malignant, metastatic, or recurrent 
tumors) requires a multimodal therapeutic approach including pharmacologic control of 
 catecholamine-mediated symptoms, radiotherapy, and systemic chemotherapy [52].
5.1. Pharmacologic management
Antihypertensive medications should be initiated in patients with biochemically active pheo-
chromocytomas, not only to manage symptoms, but also to reduce the risk of a  hypertensive 
crisis that can have devastating consequences. Initial pharmacologic  management involves 
alpha-adrenoceptor blockers (e.g., long-acting phenoxybenzamine or  short-acting prazosin, 
terazosin, or doxazosin) followed by cardioselective beta-blockade (e.g., metoprolol or aten-
olol) when necessary for reflexive tachycardia. It is important not to initiate beta-blockers 
before alpha blockade as this can lead to unopposed stimulation of alpha-adrenoceptors 
resulting in a hypertensive crisis [53]. Other hypertensive medications including calcium 
channel  blockers are occasionally prescribed for patients with refractory hypertension, 
as single agents in patients with mild hypertension or in those who cannot tolerate alpha 
blockade [54].
5.2. Pre-operative care
All patients with a known pheochromocytoma who are scheduled to undergo surgical resec-
tion should have an extensive preoperative evaluation to exclude underlying metastatic 
disease that, if present, may influence treatment approach. Preoperative pharmacologic 
blockade using appropriate antihypertensive medication and careful fluid resuscitation is 
imperative to reduce the possibility of intraoperative hypertensive crises [55]. It is recom-
mended that even patients who are normotensive preoperatively should receive alpha and 
possible  beta-blockade, as unanticipated catecholamine release by the tumor during sur-
gery may still precipitate hypertensive crisis [53]. As the alpha-blocker dose is increased, 
patients should start to have symptoms such as stuffy nose, fatigue, and mild postural 
 hypotension that reflect adequate blockade. All patients should have a comprehensive 
 anesthetic  clearance  preoperatively to assess cardiorespiratory fitness for surgery. Endocrine 
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Society guidelines recommend a high sodium diet along with sufficient fluid intake to reverse 
 catecholamine-induced blood volume contraction preoperatively to prevent severe hypoten-
sion following tumor removal [2]. Cardiovascular parameters and blood glucose should also 
be carefully monitored perioperatively.
5.3. Adrenalectomy
Adrenalectomy is the treatment of choice for pheochromocytomas [56]. A laparoscopic sur-
gical approach is the current preferred technique when technically feasible (Figure 5). It 
is associated with shorter length of stay, decreased analgesic requirements, and increased 
patient satisfaction [9, 57]. There is no consensus yet with respect to the superior laparoscopic 
approach—transperitoneal or retroperitoneal; the choice is determined by the surgeon’s 
experience and preference. In patients with bilateral pheochromoctyomas or those at risk of 
bilateral disease due to known syndromes such as MEN2 or VHL, bilateral cortical sparing 
adrenalectomy has been proposed [58]. It is important to consider underlying genotype when 
selecting patients suitable for cortical sparing adrenalectomy as patients with MEN-2A or 
VHL mutations have a high risk of bilateral tumors yet low rates of malignancy, whereas 
patients with SDHB mutations should undergo total adrenalectomy carried out due to the 
increased risk of malignancy associated with these mutations. Patients with extensive locore-
gional infiltration from malignant pheochromocytomas usually require an open procedure to 
remove the tumor and any involved organs en bloc. For patients in whom safe curative surgi-
cal excision is deemed impossible, debulking/cytoreductive surgery can improve symptoms 
caused by local invasion. For patients with benign pheochromocytomas, surgical excision 
alone is curative. However, for patients with suspected or confirmed metastatic disease, alter-
native or additional treatment modalities may be required.
Figure 5. Transperitoneal laparoscopic left adrenalectomy showing the left adrenal vein (arrow) dissected prior to 
ligation.
Pheochromocytomas
http://dx.doi.org/10.5772/67373
95
5.4. Radiotherapy
Although malignant pheochromocytomas have limited radiosensitivity, patients with  metastatic 
disease and those unsuitable for surgical intervention may be candidates for  radiotherapy. 
Radiofrequency ablation and external beam radiotherapy are modalities in current use [59]. 
Radiotherapy is also used in the treatment of unresectable head and neck  paragangliomas 
where long-term control can be obtained with limited toxicity [60]. When used in conjunc-
tion with radionuclide therapy (131I-MIBG), external radiation has been shown to improve 
response rates in a small number of patients with widespread systemic metastases [61].
5.5. Radionuclide therapy
Radionuclide treatment is indicated for patients with malignant disease in whom surgery is 
not a feasible option. Based on administration of radioactive compounds leading to the emis-
sion of beta particles into tumor cells causing their destruction, these beta-emitting isotopes 
are coupled to either 131I-MIBG or somatostatin analogs that allow uptake into chromaffin 
cells of adrenergic tissue. Patients with metastatic disease with 131I-MIBG uptake on imaging 
may be suitable for this treatment modality.
5.6. Chemotherapy
Malignant pheochromocytomas are not particularly chemosensitive. Chemotherapy is largely 
reserved for those patients not amenable to surgical therapy and who do not respond to 
radionuclide treatment. The most common regimen of cyclophosphamide, vincristine, and 
dacarbazine (CVD) has been shown to be of some value in palliating symptoms of advanced 
disease, reducing the rate of tumor growth, and occasionally decreasing tumor size [62, 63]. 
Experience with alternative chemotherapeutic agents for pheochromocytomas is limited and 
mostly based on isolated case reports and small series. Further, clinical trials are needed before 
recommendations can be made on their use in pheochromocytomas and paragangliomas [64].
5.7. Targeted therapy
Since standard adjuvant therapies have been demonstrated to have limited efficacy in  treating 
advanced pheochromocytomas, newer therapeutic targets are currently being studied. 
Underlying genetic mutations and molecular alterations associated with malignancy have led 
to the identification of molecular therapeutic targets that include the mammalian rapamycin 
(mTOR) protein kinase, which is known to be upregulated in malignant  pheochromocytomas 
[65], angiogenesis-mediated growth factors such as vascular endothelial growth  factor 
(VEGF) and heat shock protein 90 (Hsp90), which are also overexpressed in malignant 
 pheochromocytomas [66]. The mTOR inhibitor, Everolimus, has been used in a number of 
patients with malignant pheochromocytomas, but results have been disappointing [67]. This 
may be due to compensatory P13K/AKT and ERK activation in response to mTOR inhibition 
[68]. Further studies of targeting more than one pathway to overcome drug resistance are in 
progress using a combination of mTOR inhibition with other specific molecular drugs.
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Like other tumors, targeting angiogenesis-mediated tumor growth by the VEGF pathway has 
been evaluated in the treatment of malignant pheochromocytoma. Sunitinib, a  tyrosine kinase 
inhibitor that inhibits VEGF-R, PDGF, and c-KIT, was originally developed as a treatment for 
renal cell carcinoma but has shown some promising results for malignant  pheochromocytomas 
with reduction in tumor size, catecholamine secretion, and metabolic activity on  functional 
imaging [69]. Additional targets for therapy of pheochromocytomas will be identified with 
increasing understanding of tumor pathogenesis.
6. Summary
With the advent of improved diagnostic imaging and a greater understanding of molecular genet-
ics, an increasing number of patients with pheochromocytomas are being identified. The majority 
of these patients have benign disease that can be cured by minimally  invasive  surgical resection. 
The recognition of malignant potential remains a major diagnostic  challenge, and the presence 
of metastatic disease still carries a poor prognosis. Several targets for therapy have been already 
identified for further evaluation, which may offer promising therapeutic options in the future.
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